143 related articles for article (PubMed ID: 35848529)
21. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Impact of Pretreatment 2-[
Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
[No Abstract] [Full Text] [Related]
23. The role of baseline 2-[
Albano D; Calabrò A; Dondi F; Bagnasco S; Tucci A; Bertagna F
Hematol Oncol; 2024 Mar; 42(2):e3266. PubMed ID: 38444261
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
25. Clinical and Prognostic Role of 18F-FDG PET/CT in Pediatric Ewing Sarcoma.
Albano D; Dondi F; Schumacher RF; D'Ippolito C; Porta F; Giubbini R; Bertagna F
J Pediatr Hematol Oncol; 2020 Mar; 42(2):e79-e86. PubMed ID: 31135716
[TBL] [Abstract][Full Text] [Related]
26. [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].
García Velloso MJ; Boán García JF; Villar Luque LM; Aramendía Beitia JM; López García G; Richter Echeverría JA
Rev Esp Med Nucl; 2003; 22(4):217-23. PubMed ID: 12846945
[TBL] [Abstract][Full Text] [Related]
27. Utility of 18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary.
Takeuchi S; Lucchini M; Schmeler KM; Coleman RL; Gershenson DM; Munsell MF; Macapinlac HA; Ramirez PT
Gynecol Oncol; 2014 Apr; 133(1):100-4. PubMed ID: 24534359
[TBL] [Abstract][Full Text] [Related]
28. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
29. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
Caglar M; Yener C; Karabulut E
Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
[TBL] [Abstract][Full Text] [Related]
30. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
31. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of CA125 and its kinetic parameters and positron emission tomography/computed tomography (PET/CT) with fluorodeoxyglucose ([
Palomar Muñoz A; Cordero García JM; Talavera Rubio P; García Vicente AM; González García B; Bellón Guardia ME; Soriano Castrejón Á; Aranda Aguilar E
Med Clin (Barc); 2018 Aug; 151(3):97-102. PubMed ID: 29276012
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG-PET/CT in laryngeal cancer: comparison with conventional imaging and prognostic role.
Albano D; Dondi F; Paderno A; Nocivelli G; Maddalo M; Magrini SM; Nicolai P; Maroldi R; Giubbini R; Bertagna F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021; 40(4):229-238. PubMed ID: 34218885
[TBL] [Abstract][Full Text] [Related]
34. Correlation of
Mayoral M; Paredes P; Saco A; Fusté P; Perlaza P; Tapias A; Fernandez-Martinez A; Vidal L; Ordi J; Pavia J; Martinez-Roman S; Lomeña F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):80-86. PubMed ID: 28869177
[TBL] [Abstract][Full Text] [Related]
35. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
36. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
37. Preoperative PET/CT score can predict incomplete resection after debulking surgery for advanced serous ovarian cancer better than CT score, MTV, tumor markers and hematological markers.
Wang J; Liu L; Pang H; Liu L; Jing X; Li Y
Acta Obstet Gynecol Scand; 2022 Nov; 101(11):1315-1327. PubMed ID: 35979992
[TBL] [Abstract][Full Text] [Related]
38. Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
Alongi P; Caobelli F; Gentile R; Stefano A; Russo G; Albano D; Baldari S; Gilardi MC; Midiri M
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):224-233. PubMed ID: 27565154
[TBL] [Abstract][Full Text] [Related]
39.
Liu S; Feng Z; Wen H; Jiang Z; Pan H; Deng Y; Zhang L; Ju X; Chen X; Wu X
Jpn J Radiol; 2018 Sep; 36(9):544-550. PubMed ID: 29943313
[TBL] [Abstract][Full Text] [Related]
40. The relationship between CEA and CA 15-3 positivity and metabolic and volumetric 18F-FDG PET/CT parameters in preoperative evaluation of breast cancer.
Can C; Arac E; Cakabay B; Guzel Y
Ann Ital Chir; 2022; 92():33-39. PubMed ID: 35342101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]